SymBiosis Capital Partners, LLC Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0002006045

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q1 2026 Q4 2025

Q1 2026 · 6 positions · Total reported value $52.77M · Top-10 concentration 100.0% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 83.3% · 1 new · 3 cut · 6 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q4 2025 → Q1 2026): -14.8% · vs SPY -10.2% · Prev Value $109.50M — last quarter positions weighted by this quarter price moves · ranking

In its Q1 2026 13F filing, SymBiosis Capital Partners, LLC disclosed 6 equity positions with a combined reported value of $52.77M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2026 were EVMN ($29.45M), IVA ($13.06M), WVE ($5.44M). By sector, the heaviest allocations are Health Care 100.0%, Other 0.0%. Versus the prior quarter, allocation shifted toward Health Care (+15.5pp) and away from Other (-3.4pp), Communication Services (-12.1pp).

Versus the prior quarter, SymBiosis Capital Partners, LLC opened 1 new positions, trimmed 3 and fully exited 6, a turnover rate of 83.3% of positions. The portfolio's overlap with the prior quarter was 42% of names.

The largest new positions opened in Q1 2026 were WVE ($5.44M).

Of the 6 positions fully exited versus the prior quarter, the largest were VSTM ($15.44M), AMPG ($13.23M), PGEN ($12.54M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2026)

  • WVE WAVE LIFE SCIENCES INC · $5.44M

Fully Exited (vs previous quarter)

  • VSTM VERASTEM INC · prev qtr: $15.44M
  • AMPG AMPLITECH GROUP · prev qtr: $13.23M
  • PGEN PRECIGEN INC · prev qtr: $12.54M
  • NUVB NUVATION BIO INC · prev qtr: $11.20M
  • AARD Aardvark Therapeutics Inc · prev qtr: $6.26M
  • GBIO GENERATION BIO CO · prev qtr: $3.78M

Insider Transactions (Form 4)

Latest SymBiosis Capital Partners, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

SymBiosis Capital Partners, LLC is an SEC-registered 13F filer. As of Q1 2026 it reported 6 US equity positions with a combined value of $52.77M. HoldingsHub carries 2 quarters of its filings (Q4 2025–Q1 2026).

Portfolio Structure

  • 6 positions · $52.77M reported value (Q1 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: EVMN (EVOMMUNE INC) at 55.8%
  • Average position size: $8.79M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q1 2026: 1 new, 3 reduced, 6 exited
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: SymBiosis Capital Partners appears to maintain a cautious approach with a focus on Health Care sector. The slight increase in the fund's total value suggests a conservative rebalancing, possibly reflecting a belief in the stability and growth prospects of the Health Care sector. 2. Key Moves: - Added: WVE (WAVE LIFE SCIENCES INC) as a new holding, which could indicate a strategic move into biotechnology or a similar subsector. - Reduced: IVA (INVENTIVA SA ADS), RANI (RANI THERAPEUTICS HLDGS INC), and CLNN (Clene Inc) significantly, suggesting a reevaluation of these companies or sectors and a preference for other opportunities. - Hold: The fund maintained its position in EVMN (EVOMMUNE INC) and SRZNW (SURROZEN INC), showing a commitment to these holdings. 3. Portfolio Structure: - Passive/Active: The portfolio seems to be a blend, with a conservative stance in maintaining some positions and a willingness to explore new opportunities (WVE addition). - Sector Bias: Strong Health Care sector bias, with 90.27% of the portfolio invested in the sector. - Risk Appetite: Low to moderate risk appetite, as evidenced by the conservative hold and reduction in some positions, and the new addition being a single-digit percentage of the portfolio. 4. Per-Holding One-Liner: - EVMN: EVOMMUNE INC is a biopharmaceutical company focused on developing therapies for various diseases. (unverified) - IVA: INVENTIVA SA ADS is a biotechnology company specializing in the development of treatments for rare genetic disorders. (unverified) - WVE: WAVE LIFE SCIENCES INC is a biotechnology company focused on RNA modulators for genetic and neurological diseases. (unverified) - RANI: RANI THERAPEUTICS HLDGS INC is a biotechnology company focused on developing therapies for neurodegenerative diseases. (unverified) - CLNN: Clene Inc is a biotechnology company engaged in the development of therapies for neurodegenerative diseases. (unverified) - SRZNW: SURROZEN INC is a biotechnology company focused on the development of treatments for oncology and ophthalmology. (unverified) 5. One-Sentence Style Summary: SymBiosis Capital Partners held steady in the Health Care sector while selectively reducing positions in favor of a cautious yet exploratory approach, with a new addition in the biotechnology space.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Other 0.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 1.28M $29.45M 55.80%
55.80%
Hold
2 2.35M $13.06M 24.76%
24.76%
Reduce
3 750.00K $5.44M 10.30%
10.30%
New
4 3.67M $2.69M 5.11%
5.11%
Reduce
5 431.09K $2.13M 4.03%
4.03%
Reduce
6 150.00K $2.40K 0.01%
0.01%
Hold

FAQ

What did SymBiosis Capital Partners, LLC buy in 2026-Q1?

In its 2026-Q1 13F filing, SymBiosis Capital Partners, LLC reported 6 equity positions worth $52.77M in aggregate; its largest disclosed positions were EVMN ($29.45M), IVA ($13.06M), WVE ($5.44M).

How large is SymBiosis Capital Partners, LLC's portfolio?

SymBiosis Capital Partners, LLC reported $52.77M of long equity holdings across 6 positions as of 2026-Q1. Top-10 holdings account for 100.0% of reported value.

What is SymBiosis Capital Partners, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/symbiosis-capital-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →